Acta Medica Okayama volume74 issue2
2020-04 発行

The Efficacy of Software to Help Patients Understand Drug for Adjuvant Treatment for Breast Cancer: A Pilot Randomized Controlled Trial

Kuba, Sayaka Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Yamanouchi, Kosho Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Morita, Michi Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Sakimura, Chika Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Inamasu, Eiko Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science
Hatachi, Toshiko Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science
Otsubo, Ryota Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science
Matsumoto, Megumi Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science
Yano, Hiroshi Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science
Miyamoto, Junya Department of Clinical Research Center, Nagasaki University Graduate School of Biomedical Science
Sato, Shuntaro Department of Clinical Research Center, Nagasaki University Graduate School of Biomedical Science
Nakagawa, Hiroo Department of Pharmacy, Nagasaki University Graduate School of Biomedical Science
Kanetaka, Kengo Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Takatsuki, Mitsuhisa Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Nagayasu, Takeshi Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science
Eguchi, Susumu Department of Surgery, Nagasaki University Graduate School of Biomedical Science
Publication Date
2020-04
Abstract
We assessed the usefulness of ChemoCalc, a software package for calculating drug costs, in helping patients understand these costs. We randomly assigned, in a 1 : 1 ratio, 20 women who had undergone surgery for early breast cancer to a group that discussed adjuvant treatment with their physicians using the ChemoCalc software (ChemoCalc group) or a group that discussed adjuvant treatment without ChemoCalc (Usual Explanation group). The participants completed a five-grade evaluation questionnaire after these discussions. The primary endpoint was the intergroup comparison of the questionnaire scores regarding participants’ understanding of their treatment-associated drug costs. Median age was not significantly different between the ChemoCalc group and Usual Explanation group (57 vs. 50, respectively; p=0.27). Patients in the ChemoCalc group had a significantly higher perceived level of understanding of the drug cost than those in the Usual Explanation group (5 [4-5] vs. 2.5 [1-5], respectively; p=0.002). Scores related to the patients’ perception that understanding drug costs is an important part of breast cancer treatment were also higher in the ChemoCalc group than the Usual Explanation group (5 [2-5] vs. 3 [1-5], respectively; p=0.049). ChemoCalc was found to be useful for understanding drug costs.
Document Type
Original Article
Keywords
breast cancer
drug costs
ChemoCalc
Link to PubMed
Thumnail 74_2_95.pdf 5.64 MB